FATE Stock Catalyst: Fate Therapeutics Announces Data Presentation at ASGCT Annual Meeting

May 4, 2026 · 9:30am ET

Company to showcase off-the-shelf CAR T-Cell programs.

Max move

+33.8%

High of day $2.06

Sparker timei

9:30am ET

FATE · May 4, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Fate Therapeutics Inc. (Nasdaq: FATE) announced that data from its off-the-shelf CAR T-Cell programs FT819, FT839, and FT836 will be featured at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, taking place from May 11–15.

The presentation will highlight the latest advancements and research findings from these innovative programs. Fate Therapeutics, a clinical-stage biopharmaceutical company, is dedicated to the development of programmed cellular immunotherapies for oncology and immunology.

As of the latest company context, Fate Therapeutics has a free float of 101,620,000 shares.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time FATE sparks.

Download Sniper App →

Catch the next FATE-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →